Vagal A S, Leach J L, Fernandez-Ulloa M, Zuccarello M
Department of Radiology, Section of Neuroradiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0762, USA.
AJNR Am J Neuroradiol. 2009 May;30(5):876-84. doi: 10.3174/ajnr.A1538. Epub 2009 Feb 26.
The acetazolamide (ACZ) challenge test is a useful clinical tool and a reliable predictor of critically reduced perfusion. In patients with chronic steno-occlusive disease, the ability to maintain normal cerebral blood flow by reducing vascular resistance secondary to autoregulatory vasodilation is compromised. Identification of the presence and degree of autoregulatory vasodilation (reflecting the cerebrovascular reserve) is a significant prognostic factor in patients with chronic cerebrovascular disease. The pharmacologic challenge of a vasodilatory stimulus such as ACZ can also be used to optimize the treatment strategies for these patients. The pathophysiology, methods, and clinical applications of the ACZ challenge test are discussed in this article.
乙酰唑胺(ACZ)激发试验是一种有用的临床工具,也是严重灌注减少的可靠预测指标。在慢性狭窄闭塞性疾病患者中,通过自动调节性血管舒张继发降低血管阻力来维持正常脑血流量的能力受到损害。识别自动调节性血管舒张的存在和程度(反映脑血管储备)是慢性脑血管疾病患者的一个重要预后因素。诸如ACZ等血管舒张刺激的药物激发试验也可用于优化这些患者的治疗策略。本文讨论了ACZ激发试验的病理生理学、方法和临床应用。